This grant, offered by USAID, aims to advance microbicide product development and facilitate their introduction as a new HIV prevention technology. Following the successful CAPRISA 004 trial, which demonstrated that a vaginal microbicide could significantly reduce HIV infection risk, there is now a critical need to confirm product safety and effectiveness, secure regulatory approvals, and prepare for widespread introduction. This initiative focuses on meeting the urgent needs of women in developing countries. While ongoing research and development into improved and alternative microbicide products remains crucial, this grant emphasizes broader activities required to transition the USAID program towards practical microbicide introduction. It seeks to build upon existing promising leads in the product pipeline to accelerate availability and impact.
Opportunity ID: 218854
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | APS-OAA-13-000001 |
| Funding Opportunity Title: | APS for Microbicide Research, Development, and Introduction, Round 2 |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 98.001 — USAID Foreign Assistance for Programs Overseas |
| Cost Sharing or Matching Requirement: | Yes |
| Version: | Synopsis 1 |
| Posted Date: | Feb 04, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Mar 18, 2013 |
| Current Closing Date for Applications: | Mar 18, 2013 |
| Archive Date: | Apr 17, 2013 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $168,000,000 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Agency for International Development |
| Description: | The CAPRISA 004 clinical trial of 1% tenofovir gel, conducted by South African investigators and jointly supported by USAID and the Government of South Africa, was the first demonstration that a vaginal microbicide could significantly reduce the risk of HIV infection. This proof of concept, announced in July 2010, focused attention on the need to confirm the safety and effectiveness of this product, obtain regulatory approval from the relevant national authorities, and prepare for introduction of this new HIV prevention technology designed to help meet the needs of women in developing countries. Simultaneously, other promising microbicide leads are moving forward in the product development pipeline as well. Although research and development (R&D) for improved and alternative microbicide products will continue to be of interest, a new and broader range of activities is now needed to move the USAID program forward toward microbicide introduction. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Kathleen Bumpass
Contracts Specialist Phone 202-567-5008 Email:kbumpass@usaid.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 218854 Full Announcement-1 -> microbicide aps round 2 final posted 2.4.13 .pdf
Folder 218854 Other Supporting Documents-Questions and Answers 1 -> questions and answers final 030413.pdf
Packages
There are no packages on this grant.
Share This Post, Choose Your Platform!
About the Author: osnqt
